Endometrial cancer (Q86100370)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Endometrial cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alexandra Leary

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Carien L Creutzberg

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

5

Emile Darai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

4

Nadeem Abu-Rustum

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

6 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

10023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

1094-1108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Endometrial cancer: a review and current management strategies: part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Endometrial cancer: a review and current management strategies: part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Profile of women 45 years of age and younger with endometrial cancer*1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Feasibility of ovarian preservation in patients with early stage endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Endometrial cancer in women 40 years old or younger

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

USA endometrial cancer projections to 2030: should we be concerned?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Estrogen-progestin replacement therapy and endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Epidemiology of endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Association between diabetes, diabetes treatment and risk of developing endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Two pathogenetic types of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Integrated genomic characterization of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

FGFR2 as a molecular target in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

My approach to the interpretation of endometrial biopsies and curettings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Prospective comparison of biopsy results from curettage and hysteroscopy in postmenopausal uterine bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Preoperative assessment of myometrial and cervical invasion in endometrial carcinoma by transvaginal ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Three-dimensional ultrasound with volume contrast imaging for preoperative assessment of myometrial invasion and cervical involvement in women with endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Myometrial invasion in endometrial cancer: diagnostic accuracy of diffusion-weighted 3.0-T MR imaging--initial experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Endometrial cancer: preoperative staging using three-dimensional T2-weighted turbo spin-echo and diffusion-weighted MR imaging at 3.0 T: a prospective comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

A systematic review of tests for lymph node status in primary endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Molecular imaging in the management of gynecologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Potential role of multislice SPECT/CT in impingement syndrome and soft-tissue pathology of the ankle and foot

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Classification of endometrial carcinoma: more than two types

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Trends in corpus uteri cancer mortality in member states of the European Union.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Survival impact of lymphadenectomy stratified by nodal metastatic probability in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

External validation of nomograms designed to predict lymphatic dissemination in patients with early-stage endometrioid endometrial cancer: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a prospective randomized study with 11-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Adenocarcinoma of the Endometrium: Survival Comparisons of Patients with and without Pelvic Node Sampling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Type I and II endometrial cancers: have they different risk factors?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Predictors of final histology in patients with endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Sentinel Node Biopsy Upstages Patients with Presumed Low- and Intermediate-risk Endometrial Cancer: Results of a Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Validity of intraoperative gross examination of myometrial invasion in patients with endometrial cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Evaluation of the sentinel lymph node algorithm with blue dye labeling for early-stage endometrial cancer in a multicentric setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

The increasing credibility of sentinel lymph node mapping in endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Long-term outcomes after pelvic radiation for early-stage endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

External Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma—A Prospective Randomized Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Pelvic exenteration for recurrent endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Advances in the management of recurrent endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: a retrospective multi-institutional study of 426 patients in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Targeting HER2 in ovarian and uterine cancers: challenges and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Old drug, new trick: repurposing metformin for gynecologic cancers?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Emerging therapeutic targets in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions☆

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Committee opinion no. 619: Gynecologic surgery in the obese woman

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900130-0

7 January 2021

10.1016/S0140-6736(15)00130-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26354523%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference